News & Events about Ngm Biopharmaceuticals Inc.
NGM Biopharmaceuticals, Inc. (NASDAQ:NGM Get Rating) Director Group L. P. Column purchased 37,639 shares of NGM Biopharmaceuticals stock in a transaction dated Thursday, January 19th. The stock was bought at an average cost of $5.00 per share, with a total value of $188,195.00. Following the...
SOUTH SAN FRANCISCO, Calif., Jan. 12, 2023 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that David J. Woodhouse, Ph.D., Chief Executive Officer, and ...
NGM Bios three-pronged corporate strategy includes the following components: Focus internal clinical development efforts on solid tumor oncology portfolioGenerate next-generation biologics through prolific in-house discovery engineSeek partners for other NGM-discovered programs including aldafermin...
Globe Newswire
2 months ago
Poster presentation to showcase initial data from the Phase 1a monotherapy dose escalation arm of the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in patients with advanced solid tumorsILT2 and ILT4, both upregulated in certain tumor types, are believed ...
Globe Newswire
2 months ago
--Poster presentation to showcase NGM Bios in vitro and in vivo research supporting development of NGM936, a ILT3 x CD3 bispecific T cell engager product candidate engineered to direct T cell-mediated killing of ILT3-positive cancer cells-- --Oral presentation from the lab of Dr. Fabiana Pernaat the...